Effects of a New Emollient‐Based Treatment on Skin Microflora Balance and Barrier Function in Children with Mild Atopic Dermatitis

Bianchi, P; Theunis, Jennifer; Casas, Christiane; Villeneuve, Cécile; Patrizi, Annalisa; Phulpin, Chloe; Bacquey, Adeline; Redoulès, Daniel; Mengeaud, V.; Schmitt, Anne

doi:10.1111/pde.12786

Cited by 49 publications

(54 citation statements)

References 22 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, clinical studies were performed in infants, children, and adults with AD in order to assess the efficacy of an ES0-based cream in vivo; these results have been recently published and confirmed that an ES0-based cream applied twice daily decreased the SCORing Atopic Dermatitis53 and pruritus after 28 days of application 54. Furthermore, this ES0-based cream protected the skin from S. aureus proliferation and preserved microflora biodiversity.…”

Section: Resultsmentioning

confidence: 58%

Anti-inflammatory and immunomodulatory effects of <em>Aquaphilus dolomiae</em> extract on in vitro models

Ariès

Hernandez-Pigeon

Vaissiere

et al. 2016

CCID

View full text Add to dashboard Cite

BackgroundAtopic dermatitis (AD) is a common skin disease characterized by recurrent pruritic inflammatory skin lesions resulting from structural and immune defects of the skin barrier. Previous studies have shown the clinical efficacy of Avène thermal spring water in AD, and a new microorganism, Aquaphilus dolomiae was suspected to contribute to these unique properties. The present study evaluated the anti-inflammatory, antipruritic, and immunomodulatory properties of ES0, an original biological extract of A. dolomiae, in immune and inflammatory cell models in order to assess its potential use in the treatment of AD.Materials and methodsAn ES0 extract containing periplasmic and membrane proteins, peptides, lipopolysaccharides, and exopolysaccharides was obtained from A. dolomiae. The effects of the extract on pruritus and inflammatory mediators and immune mechanisms were evaluated by using various AD cell models and assays.ResultsIn a keratinocyte model, ES0 inhibited the expression of the inflammatory mediators, thymic stromal lymphopoietin, interleukin (IL)-18, IL-4R, IL-8, monocyte chemoattractant protein-3, macrophage inflammatory protein-3α, and macrophage-derived chemokine and induced the expression of involucrin, which is involved in skin barrier keratinocyte terminal differentiation. In addition, ES0 inhibited protease-activated receptor-2 activation in HaCaT human keratinocytes stimulated by stratum corneum tryptic enzyme and T helper type (Th) 1, Th2, and Th17 cytokine production in Staphylococcal enterotoxin B–stimulated CD4+ lymphocytes. Lastly, ES0 markedly activated innate immunity through toll-like receptor (TLR) 2, TLR4, and TLR5 activation (in recombinant human embryonic kidney 293 cells) and through antimicrobial peptide induction (psoriasin, human beta-defensin-2, and cathelicidin), mainly through TLR5 activation (in normal human keratinocytes).ConclusionOverall, these in vitro results confirm the marked regulatory activity of this A. dolomiae extract on inflammatory and immune responses, which may be of value by virtue of its potential as an adjunctive treatment of AD inflammatory and pruritic lesions.

show abstract

Section: Resultsmentioning

confidence: 58%

Anti-inflammatory and immunomodulatory effects of <em>Aquaphilus dolomiae</em> extract on in vitro models

Ariès

Hernandez-Pigeon

Vaissiere

et al. 2016

CCID

View full text Add to dashboard Cite

show abstract

“…These products may contain, for example, saponins, flavonoids and riboflavins from protein‐free oat plantlet extracts, or bacterial lysates from Aquaphilus dolomiae or Vitreoscilla filiformis . These lysates both improve AE lesions and influence the skin microbiome of AE patients . In vitro and clinical research data from different laboratories have provided some background information on molecular targets and possible mode of action of these active emollients ‘plus’ …”

Section: Basic Therapy Of Disturbed Skin Barrier Function and Emolliementioning

confidence: 99%

“…61 These lysates both improve AE lesions and influence the skin microbiome of AE patients. 62,63 In vitro and clinical research data from different laboratories have provided some background information on molecular targets and possible mode of action of these active emollients 'plus'. [64][65][66] Evidence of emollient efficacy Certain moisturizers could improve skin barrier function in AE and reduce skin susceptibility to irritants.…”

Section: Ingredients and Possible Risks Of Emollientsmentioning

confidence: 99%

Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I

Wollenberg

Barbarot

Bieber³

et al. 2018

Acad Dermatol Venereol

840

1,014

View full text Add to dashboard Cite

This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This first part of the guideline covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy, whereas the second part covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions. Management of AE must consider the individual clinical variability of the disease; highly standardized treatment rules are not recommended. Basic therapy is focused on treatment of disturbed barrier function by hydrating and lubricating topical treatment, besides further avoidance of specific and unspecific provocation factors. Topical anti-inflammatory treatment based on glucocorticosteroids and calcineurin inhibitors is used for flare management and for proactive therapy for long-term control. Topical corticosteroids remain the mainstay of therapy, whereas tacrolimus and pimecrolimus are preferred in sensitive skin areas and for long-term use. Topical phosphodiesterase inhibitors may be a treatment alternative when available. Adjuvant therapy includes UV irradiation, preferably with UVB 311 nm or UVA1. Pruritus is targeted with the majority of the recommended therapies, but some patients may need additional antipruritic therapy. Antimicrobial therapy, systemic anti-inflammatory treatment, immunotherapy, complementary medicine and educational intervention will be addressed in part II of the guideline.

show abstract

“…Their data were regarded to be from an AD population. The age of the participants ranged from 2 months to 62 years and both sexes were included in 10 of the 11 studies . AD was clinically characterized by SCOring of Atopic Dermatitis (SCORAD) in eight of the studies; Eczema Area and Severity Index in one; and Rajka and Langeland in one .…”

Section: Resultsmentioning

confidence: 99%

“…The age of the participants ranged from 2 months to 62 years and both sexes were included in 10 of the 11 studies . AD was clinically characterized by SCOring of Atopic Dermatitis (SCORAD) in eight of the studies; Eczema Area and Severity Index in one; and Rajka and Langeland in one . Patients with mild AD were included in two studies; moderate AD in nine; and patients with severe AD in seven .…”

Section: Resultsmentioning

confidence: 99%

The role of the skin microbiome in atopic dermatitis: a systematic review

et al. 2017

View full text Add to dashboard Cite

Dysbiosis is a hallmark of atopic dermatitis (AD). The composition of skin microbiome communities and the causality of dysbiosis in eczema have not been well established. The objective of this review is to describe the skin microbiome profile in AD and address whether there is a causal relationship between dysbiosis and AD. The protocol is registered in PROSPERO (CRD42016035813). We searched PubMed, Embase, Scopus and ClinicalTrials.gov for primary research studies applying culture-independent analysis on the microbiome on AD skin of humans and animal models. Two authors independently screened the full text of studies for eligibility and assessed risk of bias. Because of heterogeneity no quantitative synthesis was done. Of 5735 texts, 32 met the inclusion criteria (17 published: 11 human and six animal studies). The studies varied in quality and applied different methodology. The skin in AD had low bacterial diversity (lowest at dermatitis-involved sites) and three studies showed depletion of Malassezia spp. and high non-Malassezia fungal diversity. The relative abundance of Staphylococcus aureus and Staphylococcus epidermidis were elevated and other genera were reduced, including Propionibacterium. A mouse study indicated that dysbiosis is a driving factor in eczema pathogenesis. The data are not sufficiently robust for good characterization; however, dysbiosis in AD not only implicates Staphylococcus spp., but also microbes such as Propionibacterium and Malassezia. A causal role of dysbiosis in eczema in mice should encourage future studies to investigate if this also applies to humans. Other important aspects are temporal dynamics and the influence of methodology on microbiome data.

show abstract

Effects of a New Emollient‐Based Treatment on Skin Microflora Balance and Barrier Function in Children with Mild Atopic Dermatitis

Cited by 49 publications

References 22 publications

Anti-inflammatory and immunomodulatory effects of <em>Aquaphilus dolomiae</em> extract on in vitro models

Anti-inflammatory and immunomodulatory effects of <em>Aquaphilus dolomiae</em> extract on in vitro models

Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I

The role of the skin microbiome in atopic dermatitis: a systematic review

Contact Info

Product

Resources

About